about
Kimura disease accompanied with nephrotic syndrome in a 45-year-old maleEfficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trialsHistone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in miceDoxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.Aging affects epidermal Langerhans cell development and function and alters their miRNA gene expression profile.Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.Acquired reactive perforating collagenosis: A report of a typical case.The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis.Paraquat Poisoning Followed by Toxic Epidermal Necrolysis: A Report of Two Cases and Published Work Review.Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model.Naringin protects ultraviolet B-induced skin damage by regulating p38 MAPK signal pathway.Daidzein stimulates collagen synthesis by activating the TGF-β/smad signal pathway.Needle-free injection of 5-aminolevulinic acid in photodynamic therapy for the treatment of condylomata acuminata.MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo.Elevated circulating soluble interleukin-2 receptor in patients with non-segmental vitiligo in North American.Incontinentia pigmenti: case report.Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma.Yes-Associated Protein (YAP) Promotes Tumorigenesis in Melanoma Cells Through Stimulation of Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1).Management of pediatric psoriasis with acitretin: A review.A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.Effects of recombinant human parathyroid hormone (1-34)on cell proliferation, chemokine expression and the Hedgehog pathway in keratinocytes.Disruption of circulating CD4+ T-lymphocyte subpopulations in psoriasis patients is ameliorated by narrow-band UVB therapy.OnabotulinumtoxinA treatment of moderate to severe glabellar lines in Chinese subjects after laser therapy: A prospective, open-label, noncomparative study.Epigenetic downregulation of SFRP4 contributes to epidermal hyperplasia in psoriasis.An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation.Xiaoyin recipe ( ) for psoriasis induces a Th1/Th2 balance drift toward Th2 in peripheral blood mononuclear cells of experimental autoimmune thyroiditis rats.Scalp metastases as first presentation of pulmonary adenocarcinomas: a case reportIncreased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo developmentSerum miRNA expression profiles change in autoimmune vitiligo in miceNeedle-free injection of 5-aminolevulinic acid in photodynamic therapy for the treatment of non-melanoma skin cancerAn exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosisEfficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trialsCombination therapy with acitretin and glycyrrhizin in generalized pustular psoriasis with liver test abnormalities: A case seriesA small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patientsCutaneous phaeohyphomycosis caused by Pyrenochaeta unguis-hominis in a diabetic patient: A case reportInterleukin-33 Alleviates Psoriatic Inflammation by Suppressing the Th17 Immune ResponseEfficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasisInterleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammationGinsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIIIγ expression in keratinocytes
P50
Q35544313-58CD0A56-661B-45B7-916C-30AA8296F6DCQ35643453-8E0AF558-ECE4-4824-B47B-480B5C335DE9Q36351364-8BB4A976-F5AB-4992-9F82-43A5F5D01669Q36414381-F17271DD-5F46-47C0-9AF6-012750A94A62Q36576384-0E8A7124-0F6C-4275-80B1-A1E529F4FD3BQ37240967-FE9A2051-A619-4E90-912F-BA30AF3633D9Q37605640-99546EEE-E1A6-468C-AA28-B81263F9BECFQ38526898-F572E8EB-4AB0-472D-884F-F52B766CDCB8Q38558002-12A64049-CEC6-4885-AF90-1ECD2BED5EE1Q38784650-A3A1ABB3-4095-4C17-A9BE-9BA5106E685BQ38791541-2D61A2F1-F129-4AD0-B707-C0216431C9A3Q39013981-DDCD1B67-4F08-4B9A-930D-3BBC63B7873BQ42016054-E1167FB3-8E47-4901-AA3C-56E27B7F42BDQ43941329-0A7BFD70-B719-45F6-BD0D-BDAFDBFAFBE2Q44292952-D0D663E6-CFF8-44B1-8C99-3AEB061154EEQ44705626-8C11EB9F-8E4C-4672-8FC5-E6F085224DD0Q47108481-DF9AD3BC-FF34-4A3F-A647-25671B4200F6Q47133751-4659589B-1F5B-453A-B5AA-543BB0A38BD1Q47671540-31BB9F09-AB42-4F1D-9C77-BDB779D4C2FEQ48104953-0DC97361-78A6-4A8C-9770-656CA4FE6D9BQ48326905-EC0FE022-E920-42F7-8519-A7A664DB03D3Q50047832-152250CB-8870-465B-B960-0ED7D30AA178Q52654042-F786E119-E59F-4927-9913-87B3894F750BQ52677392-82EEA2CB-C472-461F-B288-447C5A5E67A5Q53563355-383AF1BA-35BE-44CB-B9DE-0841A4FDC787Q53695660-9A50992B-1D45-46A5-ABAC-FF8DA33DA814Q54325409-5C096401-1CB3-4EE7-9AA0-1E636CCF4726Q57071369-DDD4023B-D6BB-4055-9CE5-95A0144B9264Q86563553-EC9262D0-6F96-4870-A214-EB992CAD3EDBQ87053698-1F64C297-2E8F-4DE1-8495-3E5DF0B25371Q87159238-548E669D-A104-4FAF-A1FB-DCFEC0B23EABQ89074564-8CC6F22E-6EA5-44E6-A62D-9A56FBCC6474Q89500020-C5987B1D-C4F3-49F2-94FC-FD74A449AF7CQ90391441-CF06E5C5-B160-4E96-A291-3DAD46D0E21EQ90633709-D81A367E-D638-420C-8F5D-0D44716C8656Q91275299-75385D01-BB9E-4CCB-8DEE-E61E6FC704DAQ92043899-8D6E8423-98E3-4802-8900-C02E2CD0E739Q92465221-45C848EF-E491-42B4-B116-335EB1B4BD0EQ92595377-97FAE5FD-671B-4D39-A8E8-B422F47FACE3Q92639782-12C4B7A9-3D4E-4FE3-BCDA-5CCC1FA82553
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Yu-Ling Shi
@en
Yu-Ling Shi
@nl
type
label
Yu-Ling Shi
@en
Yu-Ling Shi
@nl
prefLabel
Yu-Ling Shi
@en
Yu-Ling Shi
@nl
P31
P496
0000-0002-1273-7881